🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Check out teaser Moonshine Agency #ConqueringSkinCancer documentary MD Anderson Cancer Center #EndCancer Honored to be volunteer exec producer w #melanoma friends UMD Public Health Dean Boris Lushniak Stanford Medicine Allison Betof Warner, MD, PhD & Susan Swetter Weill Cornell Medicine Jedd Wolchok bit.ly/43liIch

New #JITC short report: Regional distribution of HLA frequencies in the USA: implications for TCR-based therapies bit.ly/4k3Efw7

Congratulations to our Stanford Cancer Institute hematology/oncology graduating class of 2025 🎓🎉 Thanks to our leadership - Mullally Lab and Heather Wakelee - for helping us foster these brilliant minds to faculty positions

The Athletics playing “What doesn’t kill you makes you stronger” after that Philadelphia Phillies game is almost as good as “High Hopes” at CBP. #RingTheBell Allison Betof Warner, MD, PhD

🗓️ Hey #irAE fam, your guide to #ASCO25 🤓 Fri 5/30 1p Academ/Commun Tox Care E350 4p ASPIRE Community of Practice - yes! E253cd Sat 5/31 9:30a BiTES Arie Sun 6/1 8a Rare, Severe Cases S406 2:30p Tox incl CART E451 Mon 6/2 9:30a Bi & Multi-specific Antibodies S406 1p Beyond Checkpoint E450b

Members of the TIL Working Group are excited to be attending ASCO's annual meeting this week to learn more about the latest in TIL Cell Therapy research. #ASCO25 #TILCellTherapy #CancerResearch #OncTwitter

Dr. Pauline Funchain from Stanford Cancer Institute leading the 2025 ASPIRE Community of Practice meeting for irAEs. Fantastic panel discussion! #ASCO25

⭐️Wow! What a fantastic ASCO The ASCO Post editorial board meeting at #ASCO25 energized by visionary leaders in oncology Jame Abraham, MD, FACP george demetri Omid Hamid MD Allison Betof Warner, MD, PhD Phenomenal discussions on how to disseminate cutting-edge cancer research updates for all. Nothing beats

#ASCO25: “We’re seeing momentum in cell therapy for #RefractoryMelanoma,” says Allison Betof Warner, MD, PhD. Phase 1 data on IMA203 & OBX-115 point to durable responses & fewer toxicities. bit.ly/4kJxdfV #Melanoma #CellTherapy Stanford Cancer Institute Professor Georgina Long AO (Bluesky @gvlongphdmd) Melanoma Institute Australia Moffitt Cancer Center

Standing ovation at ⁦ASCO⁩ for the Challenge Trial. Take a look at this comparison of the magnitude of the exercise effect from Challenge versus multiple drug effects.

Powerhouse education session on Rare Melanomas at #ASCO25 covering desmoplastic, acral, uveal, and mucosal by Drs. Kendra, Orloff, and Guo - THE experts in the field. Follow Pauline Funchain for the play by play!

I’ve been in the exercise oncology field for 20 years and for all of that time, the main criticism has been “show me a well controlled RCT.” Well, here it is. Exercise following adjuvant chemotherapy for colon cancer reduced recurrence and improves OVERALL SURVIVAL! #ASCO25

Primary results of RELATIVITY-098 showing that adjuvant nivo+rela does not improve RFS over nivo alone, HR 1.01, biomarker data pointing to value of presence of tumor as a potential requirement for LAG3 blockade to improve efficacy. Neoadjuvant Nivo/rela had >60% MPR

New #JITC commentary: Role of high-dose interleukin-2 for melanoma in the age of cellular therapy bit.ly/4jwhLmm elizabeth buchbinder Kim Margolin Allison Betof Warner, MD, PhD

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing

Preoperative stereotactic radiation therapy (SRT) for resectable brain metastases was found to be safe and reduced the time to treatment completion compared to postoperative SRT. ja.ma/3HMx8tJ Subha Perni, MD Caroline Chung, MD Hussein Tawbi, MD, PhD

#ScienceSaturday ❓Can engineered T-cell therapies offer new hope for patients with advanced soft tissue sarcomas? ➡️ In this pilot study, D’Angelo (Sandra P D'Angelo, MD) of Memorial Sloan Kettering Cancer Center et al., with contributions from Dr. Mihaela Druta (Mihaela Druta) of Moffitt Cancer Center,